- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Docetaxel/Carboplatin/Bevacizumab/Erlotinib, Docetaxel/Carboplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 26
- States / cities
- Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 3,621
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Radiation Therapy, Targeted TKI therapy
- Device · Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Tumors Characterized by Genetic Abnormalities of ALK
- Interventions
- LDK378
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- cediranib maleate, pemetrexed disodium
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Detroit, Michigan
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
- Conditions
- Cancer
- Interventions
- Fentanyl sublingual spray, Placebo
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Interventions
- TAS6417, CYP Cocktail, Transporter Cocktail
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Platinum Responsive Malignancies
- Interventions
- KML-001, Cisplatin
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 6
- States / cities
- Elizabeth, New Jersey • Summit, New Jersey • Toms River, New Jersey + 3 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection, Pembrolizumab Injection
- Biological
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more
- Conditions
- Lung Neoplasm Malignant
- Interventions
- MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab, Rescue Medications
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Clermont, Florida • Chicago, Illinois • Portland, Oregon
- Conditions
- Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- escitalopram oxalate, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
- Interventions
- LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Interventions
- LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Ezabenlimab, BI 754111
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more
- Conditions
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Selumetinib
- Other · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
- Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 262
- States / cities
- Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Atezolizumab, Tiragolumab, Durvalumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 829 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- Palo Alto, California • Greeley, Colorado • Fort Myers, Florida + 21 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- Interventions
- ARQ 197 plus erlotinib, Pemetrexed, docetaxel or gemcitabine
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 13
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Weston, Florida + 10 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Circulating tumor cell chip
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- HPPH
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Newport Beach, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, triapine
- Drug
- Lead sponsor
- Vion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • Nashville, Tennessee + 1 more
- Conditions
- NSCLC
- Interventions
- Doxorubicin HCl Inhalation Solution, Docetaxel, Cisplatin
- Drug
- Lead sponsor
- Zivena
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Las Vegas, Nevada • The Bronx, New York + 2 more